Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 May 4;181(3):679–689. doi: 10.1007/s10549-020-05662-x

Figure 3. Dynamic changes in cHER2 status and patient outcomes.

Figure 3

(A) Associations between changes of cHER2 status from baseline to first follow-up and patient progression-free survival. Longitudinal monitoring of cHER2 status using serial blood samples collected from metastatic breast cancer patients with hormonal receptor (HR) positive (B) or HR-negative (C) tumor. cHER2, human epidermal growth factor receptor 2 phenotype on circulating tumor cell; PR, partial response; PD, progressive disease.